Taking a Deeper Dive: The Utilization of ctDNA and Minimal Residual Disease (MRD) to Assess Anticancer Therapeutic Response in Cancer

Tuesday, December 6, 2022

9:00 AM – 11:00 AM

Location: Mandalay Bay South Convention Center, Mandalay Bay D, Level 2

CE Credits: 2.00 contact hours

Planned in cooperation with the American College of Clinical Pharmacy
Activity #: 0217-9999-22-070-L01-P
Activity Type: Application-based
Target Audience: Pharmacist, Board-Certified Pharmacist

This session is designed to provide the necessary background and data that supports the use of ctDNA and MRD in oncology. Circulating tumor DNA (ctDNA), a form of liquid biopsy, is a noninvasive method that has become a reliable tool in oncology, both in solid tumors and hematologic malignancies. Over 850 clinical trials are currently recruiting for studies involving the use of ctDNA in solid tumor malignancies and over 1200 clinical trials involving the use of MRD in hematologic malignancies. The use of ctDNA and MRD is transforming how we detect, monitor, and determine treatment across a variety of malignancies. The increasing integration of ctDNA in clinical practice has been seen in the most common solid and hematologic malignancies and is therefore vital for oncology pharmacists to understand the data to support current and future applications of ctDNA and minimal residual disease (MRD).

This activity is approved for Board Certified Oncology Pharmacist (BCOP) recertification credit.

Learning Objectives:

Compare differences in the technologies utilized in solid tumor genomic profiling (tissue vs. plasma).
Assess the utility of measuring serial plasma cell-free (ctDNA) in therapy response assessment.
Describe minimal residual disease (MRD) testing methods.
Evaluate the impact and challenges of MRD in hematologic malignancies.

Program Chair(s)

Sandra Cuellar, PharmD, BCOP, FASHP, FHOPA

Clinical Associate Professor, Clinical Oncology Pharmacist
University of Illinois College of Pharmacy/UI Health

Moderator(s)

Sandra Cuellar, PharmD, BCOP, FASHP, FHOPA

Clinical Associate Professor, Clinical Oncology Pharmacist
University of Illinois College of Pharmacy/UI Health

Faculty Member(s)

CC

Caitlyn L. Crawford, PharmD, BCOP

Clinical Hematology/Oncology Pharmacist
Atrium Wake Forest Baptist
Sandra Cuellar, PharmD, BCOP, FASHP, FHOPA

Clinical Associate Professor, Clinical Oncology Pharmacist
University of Illinois College of Pharmacy/UI Health
David L. DeRemer, PharmD BCOP

Clinical Professor, Assistant Director of Experimental Therapeutics Group
University of Florida